Spring Bank Pharmaceuticals Inc Expected to Earn Q4 2019 Earnings of ($0.51) Per Share (SBPH)

Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Investment analysts at Jefferies Financial Group issued their Q4 2019 earnings estimates for Spring Bank Pharmaceuticals in a research note issued on Tuesday, March 12th. Jefferies Financial Group analyst M. Raycroft forecasts that the company will post earnings per share of ($0.51) for the quarter. Jefferies Financial Group also issued estimates for Spring Bank Pharmaceuticals’ FY2023 earnings at $5.69 EPS.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last released its quarterly earnings data on Monday, March 11th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.17.

SBPH has been the subject of several other research reports. Cantor Fitzgerald set a $34.00 target price on shares of Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 7th. Chardan Capital set a $45.00 target price on shares of Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, November 30th. Finally, Zacks Investment Research downgraded shares of Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Spring Bank Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $33.00.

NASDAQ SBPH opened at $10.44 on Thursday. Spring Bank Pharmaceuticals has a 1 year low of $8.14 and a 1 year high of $15.73. The firm has a market capitalization of $172.09 million, a price-to-earnings ratio of -5.58 and a beta of 0.80.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp boosted its stake in shares of Spring Bank Pharmaceuticals by 0.9% during the fourth quarter. Northern Trust Corp now owns 171,750 shares of the company’s stock worth $1,785,000 after buying an additional 1,507 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Spring Bank Pharmaceuticals by 5.9% during the fourth quarter. Bank of New York Mellon Corp now owns 43,789 shares of the company’s stock worth $454,000 after buying an additional 2,430 shares during the period. Rhumbline Advisers boosted its stake in shares of Spring Bank Pharmaceuticals by 65.3% during the fourth quarter. Rhumbline Advisers now owns 16,771 shares of the company’s stock worth $174,000 after buying an additional 6,623 shares during the period. Geode Capital Management LLC boosted its stake in shares of Spring Bank Pharmaceuticals by 8.7% during the fourth quarter. Geode Capital Management LLC now owns 116,861 shares of the company’s stock worth $1,214,000 after buying an additional 9,398 shares during the period. Finally, Blair William & Co. IL acquired a new stake in shares of Spring Bank Pharmaceuticals during the third quarter worth about $123,000. Institutional investors and hedge funds own 43.18% of the company’s stock.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.